A citation-based method for searching scientific literature

Urd Kielgast, Jens J Holst, Sten Madsbad. Curr Diabetes Rev 2009
Times Cited: 37







List of co-cited articles
202 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity



Liraglutide as additional treatment for type 1 diabetes.
Ajay Varanasi, Natalie Bellini, Deepti Rawal, Mehul Vora, Antoine Makdissi, Sandeep Dhindsa, Ajay Chaudhuri, Paresh Dandona. Eur J Endocrinol 2011
97
29

The physiology of glucagon-like peptide 1.
Jens Juul Holst. Physiol Rev 2007
24


Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study.
Daniel J Drucker, John B Buse, Kristin Taylor, David M Kendall, Michael Trautmann, Dongliang Zhuang, Lisa Porter. Lancet 2008
713
18


Effects of exenatide alone and in combination with daclizumab on beta-cell function in long-standing type 1 diabetes.
Kristina I Rother, Lisa M Spain, Robert A Wesley, Benigno J Digon, Alain Baron, Kim Chen, Patric Nelson, H-Michael Dosch, Jerry P Palmer, Barbara Brooks-Worrell,[...]. Diabetes Care 2009
95
18

The role of adjunctive exenatide therapy in pediatric type 1 diabetes.
Vandana S Raman, Kimberly J Mason, Luisa M Rodriguez, Krishnavathana Hassan, Xiaoying Yu, Lisa Bomgaars, Rubina A Heptulla. Diabetes Care 2010
60
18


Type 1 diabetes treatment beyond insulin: role of GLP-1 analogs.
Lindsay B Harrison, Pablo F Mora, Gregory O Clark, Ildiko Lingvay. J Investig Med 2013
35
20

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).
John B Buse, Julio Rosenstock, Giorgio Sesti, Wolfgang E Schmidt, Eduard Montanya, Jason H Brett, Marcin Zychma, Lawrence Blonde. Lancet 2009
16

Exendin-4 normalized postcibal glycemic excursions in type 1 diabetes.
John Dupré, Margaret T Behme, Thomas J McDonald. J Clin Endocrinol Metab 2004
92
13

Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers.
Michael A Nauck, Markus M Heimesaat, Kai Behle, Jens J Holst, Markus S Nauck, Robert Ritzel, Michael Hüfner, Wolff H Schmiegel. J Clin Endocrinol Metab 2002
399
13

Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets.
Loredana Farilla, Angela Bulotta, Boaz Hirshberg, Sergio Li Calzi, Nasif Khoury, Houtan Noushmehr, Cristina Bertolotto, Umberto Di Mario, David M Harlan, Riccardo Perfetti. Endocrinology 2003
467
10

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes.
John B Buse, Robert R Henry, Jenny Han, Dennis D Kim, Mark S Fineman, Alain D Baron. Diabetes Care 2004
935
10

Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
A Flint, A Raben, A Astrup, J J Holst. J Clin Invest 1998
909
10



Glucagon-like peptide 1 improved glycemic control in type 1 diabetes.
Margaret T Behme, John Dupré, Thomas J McDonald. BMC Endocr Disord 2003
53
10


Type 1 diabetes: recent developments.
Devasenan Devendra, Edwin Liu, George S Eisenbarth. BMJ 2004
171
10

Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats.
Loredana Farilla, Hongxiang Hui, Cristina Bertolotto, Elizabeth Kang, Angela Bulotta, Umberto Di Mario, Riccardo Perfetti. Endocrinology 2002
379
10

Insulin secretory reserve in insulin dependent patients at time of diagnosis and the first 180 days of insulin treatment.
S Madsbad, T Krarup, L Regeur, O K Faber, C Binder. Acta Endocrinol (Copenh) 1980
52
10

Once-weekly exenatide as adjunct treatment of type 1 diabetes mellitus in patients receiving continuous subcutaneous insulin infusion therapy.
Andrea N Traina, Melinda E Lull, Adrian C Hui, Toni M Zahorian, Jane Lyons-Patterson. Can J Diabetes 2014
33
12

DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes.
Thomas Blevins, John Pullman, Jaret Malloy, Ping Yan, Kristin Taylor, Christine Schulteis, Michael Trautmann, Lisa Porter. J Clin Endocrinol Metab 2011
296
10

Biology of incretins: GLP-1 and GIP.
Laurie L Baggio, Daniel J Drucker. Gastroenterology 2007
8

Evidence of GLP-1-mediated neuroprotection in an animal model of pyridoxine-induced peripheral sensory neuropathy.
TracyAnn Perry, Harold W Holloway, Ananda Weerasuriya, Peter R Mouton, Kara Duffy, Julie A Mattison, Nigel H Greig. Exp Neurol 2007
142
8

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial.
Alan Garber, Robert Henry, Robert Ratner, Pedro A Garcia-Hernandez, Hiromi Rodriguez-Pattzi, Israel Olvera-Alvarez, Paula M Hale, Milan Zdravkovic, Bruce Bode. Lancet 2009
764
8


Combination therapy with glucagon-like peptide-1 and gastrin restores normoglycemia in diabetic NOD mice.
Wilma L Suarez-Pinzon, Robert F Power, Yanhua Yan, Clive Wasserfall, Mark Atkinson, Alex Rabinovitch. Diabetes 2008
132
8

Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson's disease.
Göran Bertilsson, Cesare Patrone, Olof Zachrisson, Annica Andersson, Karin Dannaeus, Jessica Heidrich, Jarkko Kortesmaa, Alex Mercer, Elisabet Nielsen, Harriet Rönnholm,[...]. J Neurosci Res 2008
221
8

Insulin regulates glucagon-like peptide-1 secretion from the enteroendocrine L cell.
Gareth E Lim, Guan J Huang, Nina Flora, Derek LeRoith, Christopher J Rhodes, Patricia L Brubaker. Endocrinology 2009
105
8



Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials.
Sten Madsbad, Thure Krarup, Carolyn F Deacon, Jens J Holst. Curr Opin Clin Nutr Metab Care 2008
77
8



Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial.
Robert J Heine, Luc F Van Gaal, Don Johns, Michael J Mihm, Mario H Widel, Robert G Brodows. Ann Intern Med 2005
599
8



Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus.
T Vilsbøll, T Krarup, J Sonne, S Madsbad, A Vølund, A G Juul, J J Holst. J Clin Endocrinol Metab 2003
363
8


Glucagon-like peptide I reduces postprandial glycemic excursions in IDDM.
J Dupre, M T Behme, I M Hramiak, P McFarlane, M P Williamson, P Zabel, T J McDonald. Diabetes 1995
121
8

Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia.
Kristine B Degn, Birgitte Brock, Claus B Juhl, Christian B Djurhuus, Jaime Grubert, Dennis Kim, Jenny Han, Kristin Taylor, Mark Fineman, Ole Schmitz. Diabetes 2004
198
8

Effect of glucagon-like peptide-1 on alpha- and beta-cell function in C-peptide-negative type 1 diabetic patients.
Urd Kielgast, Meena Asmar, Sten Madsbad, Jens J Holst. J Clin Endocrinol Metab 2010
41
8




Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis.
Yazhou Li, Tanya Hansotia, Bernardo Yusta, Frederic Ris, Philippe A Halban, Daniel J Drucker. J Biol Chem 2003
462
8

Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial.
Richard M Bergenstal, Carol Wysham, Leigh Macconell, Jaret Malloy, Brandon Walsh, Ping Yan, Ken Wilhelm, Jim Malone, Lisa E Porter. Lancet 2010
435
8


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.